UNSPSC 51384001: Carsalam

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C8H5NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 685H843ULU, chemically known as 1,3-benzoxazine-2,4-dione but generally known as carsalam, which bears US NIH Compound Identifier 16258. European Medicines Agency schedules Carsalam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06146MIG.

UNSPSC 51384001 Carsalam (Commodity) encompasses naloxone, pharmaceutical deactivation systems, generic and over-the-counter medications, and related health-care supply chain products that state and local governments procure to support community health, emergency response, and pharmacy benefit programs. State and local purchasing offices, health departments, and cooperative purchasing alliances are the primary issuing bodies; Seminole County, Florida, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) appear as active recent buyers. The work solicited under this code includes annual supply contracts for naloxone and drug deactivation systems, direct-to-manufacturer prescription program design, and multi-state cooperative pharmaceutical sourcing agreements that connect local government facilities to authorized wholesalers and manufacturers.

Recent activity spans Florida, Texas, and Minnesota. Seminole County issued an IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, under a two-year initial term with one-year renewal option; the Texas Health and Human Services Commission posted a Request for Information (RFI HHS0017013, due April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs for self-insured group health plans and state agencies; and MMCAP (Minnesota Department of Administration), administering a multi-state cooperative, issued an RFP (S1070000015802, due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on compliance, EDI capability, and administrative fee acceptance.